Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA7E | ISIN: US2354964031 | Ticker-Symbol:
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
DALRADA FINANCIAL CORPORATION Chart 1 Jahr
5-Tage-Chart
DALRADA FINANCIAL CORPORATION 5-Tage-Chart
ACCESS Newswire
220 Leser
Artikel bewerten:
(1)

Dalrada Financial Corp.: Dalrada Financial Corporation Provides Update on Selection of New PCAOB Auditing Firm

Finanznachrichten News

SAN DIEGO, CA / ACCESSWIRE / October 17, 2024 / Dalrada Financial Corporation(OTCQB:DFCO) ("Dalrada," "the Company"), announced today that the company is currently active in the process of interviewing several PCAOB auditing firms to replace Assurance Dimensions. The company expects to engage a PCAOB auditing firm shortly and file its form 10-K for the year end June 30th. 2024.

The company received notice of resignation from Assurance Dimensions on October 11th, 2024, two business days prior to the deadline to file its June 30th, 2024, Form 10-K, as stated in the 8-K filed on October 15th, 2024, https://www.sec.gov/ix?doc=/Archives/edgar/data/725394/000168316824007149/dalrada_8k.htm. Assurance Dimensions was engaged to review the financials for the quarter ended March 31, 2024, audit the consolidated financial statements for year ending June 30th, 2024, and the subsequent quarters.

Brain Bonar, CEO of Dalrada Financial Corp. stated, "When building a company experiencing rapid growth and achieving its business goals, we must maintain agility and adaptability to stay focused on our objectives, even when faced with challenges. As Dalrada continues to expand and thrive, I'm eager to find a new audit partner who understands our diverse operations and can support our growth in the years to come."

About Dalrada Financial Corporation

Dalrada Financial Corporation (OTCQB:DFCO) is a multi-national holding company that develops, manufactures, and sells a robust suite of products and services in the Clean Energy and Health Care sectors. Dalrada's core segments include Dalrada Climate Technology, which offers cutting-edge heat pump technology for industrial and residential applications, and Genefic Specialty Pharmacy, which provides end-to-end prescription services as well as patient advocacy and support.

Dalrada consistently drives innovation that delivers maximum impact, bringing increased value to its shareholders.

For more information, please visit www.dalrada.com, and follow us on LinkedIn, Facebook, Twitter, and YouTube.

Forward-Looking Statements

Statements contained in this press release, other than statements of historical fact, particularly statements relating to cost reductions and the anticipated pre-tax savings from the cost reduction program, restructuring costs, footprint rationalization, simplifying and streamlining our operations, reducing complexity, enhancing the speed of decision-making, leveraging our sourcing capabilities and the timing of implementation and completion of the cost reduction program, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words "will," "believe," "expect," "intend," "anticipate," "estimate," "forecast," "project," "plan," and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of many events outside the Company's control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

Media contact: Michael Eslinger (meslinger@dalrada.com)

# # #

SOURCE: Dalrada Financial Corp.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.